Inventors:
David Neujahr - Atlanta GA, US
Aminu Mohammed - Atlanta GA, US
Jeffrey Rossio - Frederick MD, US
Assignee:
LIFE TECHNOLOGIES CORPORATION - Carlsbad CA
International Classification:
C40B 30/04, G01N 33/566
Abstract:
Described and disclosed are methods for determining, predicting, diagnosing, treating, and monitoring lung diseases, including bronchiolitis obliterans syndrome and acute cellular rejection in a lung transplant recipient by measuring chemokine levels in bronchoalveolar lavage (BAL) samples. The chemokine CXCL10 is measured in combination with at least one analyte selected from the group consisting of IL1RA, CXCL11, MCP-1, CXCL9, RANTES, IL-13, IL-17, IL-22, fractalkine, and eotaxin; and/or biomarkers. The present teachings also relate to methods, treatment decisions and kits for detecting and monitoring onset of lung transplant rejection in advance of clinically recognized symptoms.